Contraceptives Market - By Product, By Age Group, By Distribution Channel - Global Forecast, 2025 - 2034

Contraceptives Market Size

The global contraceptives market was valued at USD 19.9 billion in 2024 and is projected to grow from USD 21.1 billion in 2025 to USD 43.8 billion by 2034, registering a CAGR of 8.4% during the forecast period, according to Global Market Insights Inc.
 

The high market growth is attributed to the increasing global incidence of unplanned pregnancies, growing awareness of family planning and sexual health, continuous advancements in technology and product innovation, rising online and retail distribution channels, expanding access through government and NGO initiatives, among other contributing factors.
 

Contraceptives are medical methods, devices, or drugs used to prevent pregnancy by interfering with fertilization or implantation. This category contains systemic and local hormonal methods (pills, implants, injectable contraceptive, patches, IUDs), mechanical barriers (condoms, diaphragms), and rescue contraceptive pills. Beyond pregnancy prevention, select products also modulate menstrual regularity and alleviate diverse gynecological disorders.
 

Leading players in the contraceptives market include Bayer, Cooper, Organon, Pfizer, and Reckitt Benckiser Group. These companies maintain their competitive edge through continuous product innovation, global market presence, and significant investments in research and development.
 

The market has increased from USD 17.2 billion in 2021 and reached USD 19.2 billion in 2023, with the historic growth rate of 5.7%. The market growth was driven by the rising public awareness of reproductive health and family planning, concerted government support, and educational initiatives. The persistent incidence of unintended pregnancies, together with the increasing availability of sophisticated and user-centric contraceptive options, continues to sustain market momentum.
 

The global prevalence of unintended and adolescent pregnancies remains a significant healthcare challenge, with the World Health Organization (WHO) reporting that around 121 million unintended pregnancies occurred annually between 2015 and 2021. For instance, according to the United Nations Population Fund (UNFPA) 2023 report, approximately 60% of unintended pregnancies end in abortion, with 45% of all abortions considered unsafe.
 

The Centers for Disease Control and Prevention (CDC) reported that in 2022, the teen birth rate in the U.S. declined by 3% from 2021. Contraceptives help reduce maternal and infant mortality rates linked to unsafe abortions. The market demand continues to grow as more individuals seek reliable pregnancy prevention methods to enhance their reproductive health outcomes.
 

Moreover, government agencies, non-governmental organizations, and public awareness campaigns have intensified efforts to promote the advantages of family planning, safe sexual practices, and comprehensive reproductive health. This rising awareness has boosted the demand for contraceptive products among both men and women. Educational efforts are particularly effective in reducing stigma and increasing acceptance of modern contraceptives.
 

Contraceptives Market Trends

The market is witnessing significant growth, driven by the shift toward long-acting reversible contraceptives (LARCs), rising demand for non-hormonal and natural alternatives, increasing acceptance of emergency contraceptives, surging need for digital health and contraceptive app integration, among other factors that are collectively boosting the industry's growth.
 

• Long-acting reversible contraceptives (LARCs), including intrauterine devices (IUDs) and implants, are experiencing increased adoption due to their effectiveness and minimal maintenance requirements. According to the CDC, LARC use among women aged 15-49 increased from 10.3% in 2021 to 11.8% in 2023.
   
• The National Survey of Family Growth indicates that, among women aged 20-29, the adoption of IUDs alone surged by 15% over the same period. These contraceptives deliver prolonged efficacy without the need for daily adherence, and their cost-effectiveness led the U.S. Department of Health and Human Services to document a 23% increase in LARC prescriptions at federally funded clinics from 2022 to 2024.
   
• Consumers are becoming more conscious of side effects associated with hormonal contraceptives. This is driving interest in hormone-free IUDs, fertility awareness-based methods, and newer barrier devices. The market is seeing product launches catering to health-conscious and eco-friendly users.
   
• Furthermore, mobile applications and digital health platforms enable users to monitor menstrual cycles, fertility windows, and contraceptive adherence. According to the U.S. FDA, the number of approved digital contraception applications increased from 12 in 2021 to 28 in 2023. The World Health Organization reported that digital contraceptive platforms achieved a 42% increase in user compliance rates during 2022-2023.
   
• The integration of technology with contraception methods improves user compliance and facilitates informed decision-making. The U.S. Department of Health and Human Services found that the number of care providers collaborating with FemTech firms grew by 156% from 2021 to 2023, speeding the creation and adoption of digital contraceptive products. Collectively, these trends are expected to support sustained market expansion.
   

Contraceptives Market Analysis

The global contraceptives market was valued at USD 17.2 billion in 2021. The market size reached USD 19.2 billion in 2023, from USD 18.8 billion in 2022.
 

Based on the product, the market is segmented into devices and drugs. The devices segment is further bifurcated into condoms, intra-uterine devices, vaginal rings, subdermal implants, diaphragms, and contraceptive sponges. The drugs segment is further divided into oral contraceptive pills, injectable contraceptives, and topical contraceptives. The devices segment has asserted its dominance in the market by securing a significant market share of 70.2% in 2024 owing to the rising preference for long-acting reversible contraceptives (IUDs, implants) due to high efficacy and convenience, along with supportive government initiatives, is driving growth of contraceptive devices.
 

The segment is expected to exceed USD 33.5 billion by 2034, growing at a CAGR of 9.4% during the forecast period. On the other hand, drugs segment is expected to grow with a CAGR of 5.9%. The growth of this segment can be attributed to the increasing availability of oral pills and injectables, coupled with rising demand for convenient, cost-effective, and prescription-to-OTC transitions, is driving the growth of contraceptive drugs.
 

• The devices segment continues to dominate the market. Contraceptive devices such as intrauterine devices (IUDs) and implants provide highly effective, long-term pregnancy prevention. Their fit-and-forget nature reduces user dependency and non-adherence issues compared to daily pills. This reliability drives higher adoption among women seeking consistent protection.
   
• Many consumers are shifting toward non-hormonal devices such as copper IUDs and condoms to avoid side effects of hormonal methods. These alternatives are particularly attractive for women with health conditions or contraindications for hormone-based contraception. The demand for natural, safe, and sustainable devices continues to rise.
   
• Additionally, governments and global health organizations promote devices like IUDs and condoms as cost-effective solutions for family planning. Subsidies, free distribution programs, and inclusion in public healthcare schemes increase accessibility. This support particularly boosts adoption in low- and middle-income countries.
   
• The drugs segment was valued at USD 5.9 billion in 2024 and expected to grow during the forecast period. Oral contraceptive pills and hormonal patches remain popular contraceptive methods due to their convenience and established usage patterns. According to the CDC's National Survey of Family Growth (2022), 14% of women aged 15-49 in the U.S. use oral contraceptive pills, making them the second most common contraceptive method.
   
• The World Health Organization reported in 2023 that hormonal patches saw a 12% increase in adoption rates among women aged 18-25 across developed nations. These characteristics make pharmaceutical contraceptives particularly appealing to younger women, with the FDA's 2023 data showing that 65% of oral contraceptive users are between ages 18-29.
   
• Furthermore, advancements in drug formulation such as low-dose regimens, extended-cycle pills, and long-acting injectable contraceptives have successfully mitigated safety concerns and minimized adverse effects. The expanded options not only bolsters compliance but also addresses the demand for flexible and dependable contraceptive solutions. Growing pharmaceutical research and development continues to strengthen this segment, thereby leading to the segmental growth.
   

Based on age group, the contraceptives market is segmented as 15 - 44 years and above 44 years. The 15 - 44 years segment dominated the market in 2024 accounting for USD 18.5 billion and is anticipated to grow at a CAGR of 8.5% during the forecast period.
 

• The 15-44 years age group represents the most fertile and sexually active population segment. Contraceptives are in high demand as individuals in this range seek family planning, birth spacing, and prevention of unintended pregnancies. This makes them the core consumer base of the market.
   
• Young adults and women in their 20s and 30s are increasingly prioritizing higher education and career advancement. Contraceptives enable them to delay parenthood and exercise greater control over life choices. This lifestyle-driven need fuels demand for both short- and long-term contraceptive methods.
   
• Moreover, awareness campaigns, school health programs, and digital platforms are educating young people about safe sex and contraceptive options. This awareness reduces stigma and increases acceptance, especially for modern methods like pills, IUDs, and condoms. The trend is particularly strong in urban and developed markets.
   
• The above 44 years segment is expected to see the significant growth over the forecast period. The segmental growth is driven by the need for pregnancy prevention during perimenopause, as women may still be fertile until menopause is complete. This segment often prefers long-acting and non-hormonal methods, such as copper IUDs, due to safety concerns and contraindications with hormonal therapies.
   
• Additionally, contraceptives in this age group are increasingly used for non-contraceptive benefits, such as managing heavy menstrual bleeding, regulating cycles, and reducing risks of certain gynecological conditions. Rising awareness among older women and physician recommendations further support adoption in this demographic, thereby driving this segment's growth in the market.
   

Based on distribution channel, the contraceptives market is classified into retail pharmacies, hospital pharmacies, online channels, and other distribution channels. The retail pharmacies segment dominated the market with a revenue share of 45.8% in 2024 driven by wide accessibility, trusted pharmacist guidance, and convenient over-the-counter availability of contraceptives.
 

• The top three distribution channel segments account for over 93.3% of the total market value. The retail pharmacies segment dominated the market since they are widely accessible, convenient, plus consumers trust them. Retail pharmacies serve as the primary point of purchase for contraceptives due to their strong presence in both urban and rural areas, ensuring easy product availability.
   
• Trained pharmacists are present so they offer guidance thus strengthening consumer preference for this channel. Confidentiality as well as discreet purchasing options also strengthen consumer preference for this channel. Sales have been increased via calculated collaborations between pharmaceutical companies and retail chains and promotional discounts and loyalty programs. Retail pharmacies grow because people use contraceptives plus products available over-the-counter.
   
• The hospital pharmacies segment has captured the second position in the end-use segment and is expected to grow at a CAGR of 7.9% driven by multiple factors. Increasing hospital admissions due to chronic and acute conditions have increased the need for dependable access to cutting-edge therapies and medications. Hospital pharmacies increase patient compliance using integrated care, prescription accuracy, and timely drug availability. These pharmacies thus ensure superior outcomes for patients.
   
• Complex diseases grow in prevalence as they require specialty medications so personalized treatment approaches rise in adoption thus their role strengthens further. Patient trust and market growth are improved as a result of hospital-based clinical support, stringent safety standards, and also collaborations with pharmaceutical companies.
   
• The online channels segment was valued at USD 3.5 billion in 2024 and is expected to witness a steady growth in the forecast period. The online channels segment is driven by rising consumer preference for convenient, discreet, and accessible purchasing options, supported by expanding e-commerce platforms, digital health solutions, and subscription-based services. Growing internet penetration, improved logistics, wider product availability, and competitive pricing further accelerate adoption, making online channels a key growth driver in the market.
   

North America dominated the global contraceptives market with the highest market share of 38.6% in 2024.
 

• The U.S. market was valued at USD 6.5 billion and USD 6.9 billion in 2021 and 2022, respectively. The market size reached USD 7.3 billion in 2024, growing from USD 7 billion in 2023 and is anticipated to grow at a CAGR of 6.6% between 2025 to 2034 period.
   
• North America led the market in 2024 due to its strong healthcare infrastructure, high awareness levels, and helpful government initiatives for better reproductive health. The region benefits from the presence of well established medical device and pharmaceutical companies. These companies make sure that they consistently make a wide range of contraceptive products available, such as oral pills, injectables, intrauterine devices, implants, and also condoms.
   
• Increasing awareness among younger demographics, coupled with changing lifestyle preferences and delayed family planning trends, is also fueling demand. Additionally, technological advancements in product design, such as hormone free IUDs, extended-use implants, and user-friendly digital fertility tracking devices, are enhancing consumer confidence and adoption.
   
• With its large population, progressive insurance coverage for contraceptive products, and encouraging policies like federal and state-funded programs that provide affordable or free contraceptives to underserved communities, the U.S. in particular plays a key role with high market penetration.
   
• The increasing awareness among younger demographics has also fueled the market. Lifestyle preferences are indeed changing, so trends in family planning are delaying it. Hormone-free IUD, extended-use implants, and user-friendly digital fertility tracking devices increase consumer confidence and adoption through product design's technological advancements.
   
• Consumers are being provided with greater convenience, privacy, with choice in contraceptive purchases by e-commerce's and subscription-based models' growing influence. Furthermore, sexually transmitted infections (STIs) are rising in prevalence thus increase the demand for barrier contraceptives like condoms.
   

Europe contraceptives market accounted for USD 4.5 billion in 2024 and is anticipated to show lucrative growth over the forecast period.
 

• One of the primary drivers is the rising awareness regarding family planning and reproductive health, supported by government initiatives, educational programs, and strong advocacy from non-profit organizations. The increasing prevalence of delayed pregnancies, coupled with lifestyle changes and a growing number of working women, is further boosting the demand for reliable contraceptive options across the region.
   
• Additionally, supportive regulatory frameworks with reimbursement policies in several European countries encourage people to adopt modern contraceptive methods like intrauterine devices (IUDs), implants, injectables, also hormonal contraceptives, and barrier methods like condoms. Growing emphasis on reducing unintended pregnancies and abortion rates has also led to the integration of contraceptive counseling services into primary healthcare systems, thereby improving accessibility.
   
• Contraceptives give consumers more convenience, privacy, and a greater number of choices. Market penetration increases as availability grows through physical pharmacies and online avenues. Due to minimization of side effects with improved safety profiles, technological advancements plus innovation in product formulations, including low-dose hormonal pills and long-acting reversible contraceptives (LARCs), have also improved adoption.
   
• Furthermore, the region’s aging population and extended reproductive planning, and government-led sexual health campaigns target adolescents and young adults, that demand strengthens. A suitable healthcare infrastructure backs these factors. The factors do also increase consumer awareness and encourage social acceptance of contraceptive use in order to collectively drive sustained growth in the Europe market.
   

The Asia Pacific contraceptives market is anticipated to grow at the highest CAGR of 10.4% during the analysis timeframe.
 

• The region has a large and growing reproductive-age population, particularly in countries such as India, China, Indonesia, and the Philippines, which is creating a substantial demand for effective birth control solutions. Rising awareness of family planning programs, supported by government initiatives and international organizations like the UNFPA, has significantly increased the acceptance of contraceptive methods across both urban and rural areas.
   
• Furthermore, rapid urbanization coupled with lifestyle changes encourage couples as they delay parenthood plus as they limit family size so they increase adoption of modern contraceptives including oral pills intrauterine devices (IUDs) and condoms. Emerging economies economically developed, for people to access healthcare infrastructure, pharmacies, and online platforms. These conditions did make contraceptives to be more widely available. In addition to that, given that digital health campaigns as well as social media platforms have expanded, sexual health education has been improved, stigma has been reduced, plus knowledge regarding safe contraceptive practices has improved.
   
• Growing female workforce participation and rising emphasis on women’s health empowerment are also key drivers as more women actively make decisions regarding their reproductive health. The market is further supported by the entry of global players, local manufacturers, and the launch of cost-effective generic products that ensure affordability in price-sensitive countries.
   

The Latin America contraceptives market is experiencing robust growth over the analysis timeframe.
 

• One of the primary drivers is the region’s rising awareness of family planning and reproductive health, supported by increasing government and non-government initiatives to improve access to contraceptive methods. With a growing population and high birth rates in several countries, there is mounting pressure on healthcare systems to provide affordable and effective contraception to manage population growth and reduce unintended pregnancies.
   
• Expanding educational campaigns are playing a major role specifically as they target women plus adolescents for breaking cultural stigmas also promoting the safe use of contraceptives. Furthermore, urbanization grows so lifestyle patterns do shift, which thus increases acceptance of modern contraceptive methods as are oral contraceptives, condoms, implants, plus intrauterine devices (IUDs).
   
• In key markets such as Brazil, Mexico, and Argentina, disposable incomes are improving as a result of economic growth. Branded contraceptive products enjoy increased advanced access due to this improvement. For increased adoption, international organizations along with NGOs are actively working throughout the region to close the divide in contraceptive availability, particularly in underserved rural areas.
   
• Technological advancements, such as digital health platforms and telemedicine, are further simplifying access by offering remote consultations and online distribution of contraceptives. Alongside this, rising female workforce participation is strengthening the demand for effective family planning solutions, as women seek better control over reproductive choices to balance professional and personal lives.
   

The Middle East and Africa contraceptives market is experiencing robust growth over the analysis timeframe.
 

• The MEA market is witnessing robust growth, driven by a combination of demographic, social, and healthcare factors. Rising awareness regarding family planning and reproductive health, supported by government initiatives and non-governmental organizations (NGOs), has significantly boosted demand.
   
• Increasing population growth, particularly in countries with high fertility rates, has further created the need for effective contraceptive solutions. Expanding healthcare infrastructure and improved access to modern contraceptive methods, including oral pills, intrauterine devices (IUDs), and condoms, are strengthening market adoption. In addition, the rising involvement of international health organizations such as the WHO and UNFPA in promoting contraceptive use and funding awareness programs is fostering uptake.
   
• The growing participation of women in the workforce, coupled with urbanization, is contributing to changing attitudes toward planned parenthood and delayed pregnancies. Furthermore, advancements in distribution channels, particularly through pharmacies, clinics, and increasingly online platforms, are making contraceptives more accessible.
   
• Supportive government policies aimed at reducing maternal mortality and ensuring better reproductive health outcomes are also encouraging adoption.
   

Contraceptives Market Share

• global market presents a competitive in nature landscape, characterized by the presence of both global leaders and numerous regional players. Key players such as Bayer, CooperSurgical, Pfizer, Organon, and Reckitt collectively accounts for 42% of the total market share, leveraging their strong product portfolios, and global distribution networks. The global contraceptives market presents a moderately consolidated structure, with a few dominant multinational players holding significant shares, while numerous regional and local companies contribute to competitive fragmentation.
   

The leading players collectively capture a notable portion of the market by leveraging their extensive distribution channels, brand recognition, and ability to invest heavily in research and development to introduce innovative and effective contraceptive solutions. Their strength lies not only in product diversification across oral contraceptives, condoms, intrauterine devices (IUDs), and implants but also in integrating digital health services to enhance accessibility and user engagement.
 

Mid-tier and regional companies, on the other hand, play a crucial role in addressing niche markets and providing affordable alternatives, particularly in emerging economies where cost sensitivity remains high. This dynamic allows them to compete effectively despite the dominance of global brands. Furthermore, collaborations with governments, NGOs, and healthcare providers enhance market penetration, particularly in rural and underserved areas.
 

The market also reflects a trend toward strategic partnerships, mergers, and acquisitions aimed at expanding geographic presence and strengthening product portfolios. The competitive environment is further influenced by regulatory frameworks, patent protections, and ongoing pricing pressures, particularly in public healthcare systems. As consumer demand shifts toward long-acting reversible contraceptives and non-hormonal options, companies are increasingly focused on product innovation and differentiation to sustain growth.
 

Overall, the market share distribution highlights a balance between global players driving innovation and regional manufacturers ensuring affordability and accessibility, creating a competitive yet opportunity-rich landscape for the contraceptives industry.
 

Contraceptives Market Companies

Few of the prominent players operating in the contraceptives industry include:

• Agile Therapeutics
• Bayer
• Church & Dwight
• CooperSurgical
• Evofem Biosciences
• Exeltis
• HLL Lifecare (India)
• HRA Pharma / Perrigo (OTC)
• LifeStyles Healthcare
• Mayne Pharma
• Medintim (Kessel)
• Organon
• Pfizer
• Pregna International
• Reckitt
   
• Bayer

Bayer’s USP in the contraceptives market lies in its leadership in hormonal contraceptives, particularly oral pills and intrauterine devices (IUDs). With strong clinical validation, global reach, and continuous innovation, Bayer positions itself as a trusted provider of effective, safe, and long-acting contraceptive solutions for diverse patient needs.
 

• Church & Dwight

Church & Dwight differentiates itself with its well-recognized Trojan brand, dominating the condom segment in the U.S. Its USP lies in strong brand loyalty, wide retail availability, product variety, and emphasis on quality and innovation, making it a household name in barrier contraceptive solutions.
 

• CooperSurgical

CooperSurgical’s USP stems from its strong expertise in women’s health and fertility management, offering advanced intrauterine devices (IUDs) and contraceptive technologies. Its focus on clinical efficacy, physician partnerships, and global presence ensures it remains a key provider of long-term, reliable, and medically integrated contraceptive solutions worldwide.
 

Contraceptives Industry News:

• In March 2024, Perrigo Company plc announced the U.S. availability of Opill, its oral contraceptive pill, now offered without a prescription. Additionally, Opill is accessible through online sales on the company’s website, marking a milestone in improving consumer access and convenience within the contraceptives market.
   
• In October 2023, Xiromed LLC launched its new vaginal ring, EnilloRing, in the U.S. market as a generic version of NuvaRing. The introduction of EnilloRing enables Xiromed to address the growing demand for affordable contraceptive options, expanding its presence and accessibility within the U.S. contraceptives landscape.
   
• In April 2023, Veru Inc. entered into a distribution agreement with Afaxys Group Services, LLC (AGS) to expand access to the FC2 Female Condom. Through AGS’s Group Purchasing Organization (GPO), the partnership aims to serve over 31 million individuals relying on public health and community centers, enhancing contraceptive availability for both women and men.
   
• In March 2023, NEXT Life Sciences, Inc., a medical device company, introduced Plan A, a new reversible male contraceptive. Designed as a safe and effective birth control solution for men, Plan A highlights innovation in male-focused contraceptives, expanding choices beyond traditional female-centered methods.
   
• In February 2021, Amneal Pharmaceuticals, Inc. received FDA approval for its generic version of Ortho Evra contraceptive patch, prescribed for pregnancy prevention. This approval strengthens Amneal’s contraceptives portfolio by offering a cost-effective alternative to branded products and reinforces its competitive positioning in the U.S. market.
   

The contraceptives market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 - 2034 for the following segments:

Market, By Product

• Devices                  
  • Condoms      
    • Male
    • Female
  • Intra-uterine devices         
    • Hormonal IUD
    • Copper IUD
  • Vaginal rings 
  • Subdermal implants 
  • Diaphragms  
  • Contraceptive sponges       
• Drugs          
  • Oral contraceptive pills      
  • Injectable contraceptives   
  • Topical contraceptives         

Market, By Age Group

• 15 - 44 years
• Above 44 years

Market, By Distribution Channel

• Retail pharmacies
• Hospital pharmacies
• Online channels
• Other distribution channels

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE